Thursday, 12th February

Tracks
Lorne Cancer

Search
Speakers

1:55PM - 4:20PM

Novartis Lecture Theatre

Chair: David Vaux

Australian Melanoma Genome Project - Nick Hayward
Genetic and genomic determinants of response and resistance to targeted therapies in melanoma - Katherine Nathanson
Targeting Rab27a to suppress melanoma proliferation and invasion - Kimberley A Beaumont
Convergent de-differentiation during intra-patient evolution in therapy naïve melanoma. - Clare G Fedele
Drug Therapies in Melanoma – where to next? - Georgina Long

4:20PM - 5:00PM

Thursday, 12th February

Exhibition Hall

5:00PM - 6:00PM

Thursday, 12th February

Novartis Lecture Theatre

Chair: Nick Hayward

Towards Deciphering the Functional Genetics Landscape in Melanoma - Yardena Samuels

6:00PM - 7:30PM

Thursday, 12th February

7:30PM - 10:00PM

Thursday, 12th February

Exhibition Hall

Role of Timeless and the Androgen Receptor in Prostate Cancer - Reidun Aesoey
Evaluation of circulating MicroRNAs Biomarkers for Colorectal Adenocarcinomas in Saudi patents by Next-Generation Sequencing - Yazeed A Al-SHeikh
Targeting Solid Tumours with 2^nd Generation Proteasome Inhibitors - Alaknanda Alaknanda
Novel therapeutics for melanoma: targeting the cell cycle - Shatha AbuHammad
Targeting Hdmx to Treat Luminal Breast Cancer - Panimaya Jeffreena Miranda Alphonse Miranda
Growth-inhibitory and mucin-depleting effects of bromelain and N-acetylcysteine on mucin-expressing gastrointestinal cancer cells in vitro and in vivo - Afshin Amini
Targeting Dynamin II to Treat Glioblastoma Multiforme - Stephanie C Amiridis
Characterisation of inducible Cre recombinase activity in mouse radial glia in a novel Fabp7-CrePR mouse. - Mathew Ancliffe
MicroRNA signatures reveal pathways underlying EMT-like phenotypes in malignant melanoma. - Miles Andrews
Understanding and Overcoming Glioblastoma Resistance to Current Therapy - Zammam Areeb
AN IN VITRO DRUG SENSITIVITY TESTING PLATFORM FOR HIGH RISK CHILDHOOD CANCER PATIENTS - Greg Arndt
The ACRF Drug Discovery Centre: Services and case studies - Tim Failes
Quiescence as a marker of treatment resistance in GBM - Ryan J Atkins
Targeting Oestrogen-Dependent Breast Cancer: Ghrelin Receptor Agonists As Novel Therapeutics - CheukMan Cherie Au
Characterising the molecular function of Inhibitor of Differentiation 4 in poor prognosis basal-like breast cancer - Laura Baker
A role for adipocyte lipolysis in breast cancer progression - Seher Balaban
The molecular basis of improved haematopoiesis in patients with myelodyplastic syndrome treated with iron chelation therapy - Ashish Banerjee
The utility of circulating tumor cells and DNA in cancer therapy - Therese M Becker
Identification of a recurrent mutation in RQCD1 in melanoma - Andreas Behren
Characterisation of ADAMTS-15: a potential tumour suppressor gene in Prostate cancer - Marley J Binder
Dichloroacetate can overcome drug resistance via decreased ABC drug transporter expression and PDK2 inhibition. - Anneke C Blackburn
Disruption of the vitamin D pathway associates with SuprMam1,a breast cancer susceptibility locus in mice. - Anneke C Blackburn
Post-translational regulation of the BCL-2 family protein A1/BFL-1 - Margs S Brennan
Sca-1 delineates an estrogen receptor positive stem/progenitor subset in the mammary gland - Kara Britt
Coexpression analysis of the cancer stem cell markers CD133 and CD44 identifies distinct subtypes of glioblastoma multiforme - Daniel V Brown
DNA damage signalling in the recruitment of human telomerase to telomeres - Tracy Bryan
The contribution of stromal caveolin-1 to breast cancer metastasis - Allan D Burrows
A novel in vivo assay to determine the role of Hsp27 in breast cancer metastasis - Allan D Burrows
Sentinel lymph node detection and in vivo/ex vivo assessment of melanin distribution by means of multispectral optoacoustic tomography in patients with malignant melanoma - Neal Burton
Dynamic contrast enhanced multispectral optoacoustic tomography (DCE-MSOT) for in vivo tracer imaging of tumor heterogeneity. - Neal C Burton
Type I Interferon in Melanoma Therapy - Anthony Buzzai
Investigating acquired resistance to novel Pol I transcription inhibitors for the treatment of hematologic malignancies - Don Cameron
Network based identification of estrogen receptor-positive breast cancer risk mechanisms - Thomas M Campbell
Effects of AT₁R inhibition on mammary tumour development - Ashwini Chand
The effects of hypoxia on tumour progression in breast cancer - Anna Chen
A mouse model of CLL (chronic lymphocytic leukemia) - Hui San Chin
Modeling breast cancer dormancy and re-emergence - Amanda M Clark
Structural variations as a method for phylogenetic reconstruction of tumour evolution - Marek Cmero
Electron microscopy study of human telomerase - Scott Cohen
Next generation amplicon based sequencing of TERT promoter mutations in melanoma cell lines and formalin fixed paraffin embedded clinical samples - Andrew J Colebatch
Targeting the Nuclear Transcription Factor MYB using a Novel DNA Vaccine Combined with anti-PD-1 immune Checkpoint Therapy - Ryan S Cross
Accurate stratification of neuroblastoma patients through patient-specific simulations of signalling pathway dynamics. - David R Croucher
CHARACTERISATION OF A CHECKPOINT AND REPAIR RESPONSE TO UVB-EXPOSURE THAT IS COMMONLY DEFECTIVE IN MELANOMA - Mareike Dahmer-Heath
Parity does not decrease stem cell activity in mammary stem cell enriched populations - Genevieve Dall
Reducing Glioblastoma Multiform malignancy through the reactivation of the cAMP/PKA/CREB pathway - Paul Daniel
Deciphering the role of caspase-2 in protecting against genetic instability and tumour supression. - Swati Dawar
Whole-exome sequencing of matched fresh and formalin-fixed paraffin embedded melanoma tumours: relevance for clinical decision making - Ricardo De Paoli-Iseppi
Coordinated targeting of RNA Polymerase I transcription and PI3K/AKT/mTOR signalling: a novel therapeutic approach to treat MYC-driven B-lymphoma - Jennifer R Devlin
The Bcl11a inhibitor simvastatin eliminates leukaemic stem cells - Philipp A Dietrich
A comprehensive and systematic analysis of miRNA function in neuroblastoma - Eoin Dodson
Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer - Tanya Dwarte
The role of the polarity protein, Par3, in haematopoiesis. - Sarah Ellis
Intratumoural heterogeneity in glioblastoma revealed using a novel profiling approach based on cell proliferation - Berwini Endaya
A NOVEL SERIAL BIOPSY METHOD TO EVALUATE REPSONSE TO TREATMENT IN BRAIN TUMOUR MOUSE MODELS - Raelene Endersby
PRMT5 inhibitors as novel treatment for cancers - Hendrik Falk
Targeted molecular therapies for HPV driven cancers. - SORA FALLAHA
Investigating the role of the MITF-BRN2 expression axis in metastatic melanoma - Mitchell Fane
Cytokine signalling in haematopoietic cells - Karla C Fischer
Microglia secrete and respond to cyclophilin A: Evidence for the pro-tumourigenic role of cyclophilin A on glioblastoma cells - Gurkiran K Flora
Characterisation of CMV-expanded NK Cell Subsets with Enhanced Function in Transplant Recipients with Haematological Cancers - Bree Foley
The ETS transcription factor ELF5 drives lung metastasis in luminal breast cancer via recruitment of Gr-1+CD11b+ myeloid derived suppressor cells. - David Gallego Ortega
E6AP is a novel regulator of the INK4/ARF locus: implications for NSCLC - Cristina Gamell
Comparison of Zinc Finger and RNA-guided CRISPR-based Artificial Transcription Factors to reactivate the endogenous transcription of a dormant Tumor Suppressor Gene. - Benjamin Garcia-Bloj
Heterogeneous Subclones of Circulating Tumour Cells (CTCs) Detected in Blood of Patients with Solid Tumours - Christin Gasch
Targeting FRMD4A and the Hippo Pathway in the management of squamous cell carcinoma. - Stephen J Goldie
Targeting pro-survival Bcl-2 proteins for treating multiple myeloma - Jianan Gong
Analysis of Circulating Tumour DNA to Monitor Systemic Therapy Response and Escape Mutations in Metastatic Melanoma - Elin S Gray
Exploring the Involvement of E6AP in Prostate Cancer Using a Proteomic Approach - Twishi Gulati
Inositol polyphosphate 4-phosphatase II promotes PI3K signaling and functions as an oncogenic regulator in human colon cancer - Su Tang Guo
MITF expression levels define dynamic melanoma heterogeneity - Nikolas K Haass
Melanoma cells in G1 phase escape proteasome inhibitor cytotoxicity - Nikolas K Haass
PAI-2 (SerpinB2) Inhibits Pancreatic Cancer Cell Invasion. - Nathanial Harris
Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance - Yaowu He
Co-targeting histone deacetylases and BET proteins significantly induces apoptosis in melanoma cells - Anja Heinemann
Design, synthesis and biological evaluation of nucleotide pro-labels for visualising DNA synthesis in proliferating cells - David Hilko
Transcriptional regulation of mammary lineage commitment by Inhibitor of Differentiation 4 (Id4) - Holly Holliday
Monitoring response to therapy in melanoma by quantification of circulating tumour DNA with droplet digital PCR - Christopher Hudson
Regulation of sarcoma cell invasion and invadopodia formation by AFAP1L1 through a Lyn/SFK-AFAP1L1-Nck/Vav2 pathway - Evan Ingley
Identification of the critical p53 tumor suppression mechanisms in vivo - Ana Janic
MicroRNA regulation of inositol polyphosphate 4-phosphatase II to modulate melanocytic cell proliferation through PI3K/SGK3 signaling - Chen Chen Jiang
Receptor-Interacting Protein Kinase 1 Functions as an Oncogenic Regulator in Human Melanoma - Lei Jin
Intravital imaging reveals tumour-associated macrophages as targets of bisphosphonates in vivo - Simon Junankar
Investigating the role of PIM-1 kinase in breast cancer brain metastasis - Lara Jupp
Amino acids stimulate rDNA transcription through mTORC1-S6K1 signalling and MYC transcription factor - Jian Kang
Crosstalk between ErbB2 and breast cancer associated receptor tyrosine kinases in resistance to ErbB2 targeted therapies. - Sean Mr Kennedy
THE ROLE OF CELL DEATH MEDIATORS IN REPROGRAMMING TO PLURIPOTENCY - Esther Kim
Efficacy of Two Novel HDAC Inhibitors against Brain Metastatic Breast Cancer - Soo Hyun Kim
Deciphering the biology of cancer stem cells in triple-negative breast cancer - Christina Konrad
The predictive value of ARv7 expression in localized prostate cancer treated with "super-castration" therapy. - Natalie J Kurganovs
Using genome-wide analysis of translational activity to investigate the response of cancer cells to therapies targeting the ribosome - Eric P Kusnadi
Characterisation of novel molecular targets to inhibit lung cancer metastasis - Jill E Larsen
IDH1 mutation as a novel therapeutic target in cholangiocarcinoma - David Lau
Neural Signalling Remodels Lymph Vasculature for Metastatic Dissemination - Caroline Le
Receptor Tyrosine Kinases differ in their ability to confer resistance to Vemurafenib (PLX4032) treatment in BRAF^V600E melanoma. - Frederic Li
Oxidative burst produced by the NOX2 complex does not play a role in methylcholanthrene induced sarcoma development - Maarten A Ligtenberg
Targeting the PI3K/PTEN/Akt/mTOR Pathway in Sarcoma Cell Lines - Hui Jun Lim
Role of Focal Adhesion Kinase Inhibitor in Lysophosphatidic Acid-induced Migration in Glioma Stem Cells - Kai Zheong Lim
Towards a structural understanding of the cell polarity regulator and tumour suppressor protein, Scribble - Krystle YB Lim
A predictive, exosome-based signature for metastatic progression in Non-Small-Cell Lung Cancer patients - Richard Lobb
The role of ETS Homology Factor (EHF) in loss of cell differentiation in colon cancer - Ian Y Luk
Novel clinical relevant combined therapies to overcome apoptosis resistance in Acute Myeloid Leukemia - Chunyan Ma
Targeting Triple Negative Breast Cancer Brain Metastases - Joanna Macdonald
The role of Myb protooncogene in intestinal stem cells and cancer - Jordane Malaterre
A specific expression signature accurately predicts high grade prostate tumours in fat but not from adjacent benign tissues. - stefano mangiola
Temporal and spatial regulation of Yorkie during Drosophila melanogaster wing development - Samuel A Manning
Mechanisms of response and resistance to the CDK4/6 Inhibitor PD991 in Melanoma - Claire Martin
Thyroid tumours: insights into their molecular differences and novel candidate protein markers to improve cancer diagnosis - Juan Martinez-Aguilar
Expression of Sprouty 1 protein (Spry1) is downregulated in human epithelial ovarian cancer and associated with clinicopathological features and patient outcome. - Samar Masoumi-Moghaddam
THE IKAPPAB KINASE, REGULATES B-CELL LYMPHOMA-2 INTRINSIC APOPTOTIC PROTEINS, DOWNSTREAM OF BETA COMMON RECEPTOR CYTOKINE SIGNALLING - Dimitra Masouras
MSH2 and prostate cancer; a dangerous mismatch - Patrick McCoy
Redirecting immune subsets through genetic manipulation for enhancing adoptive immunotherapy. - Carmen SM Yong
Targeting GLUT6 and glycolytic-lipogenic metabolism in endometrial cancer - Frances L Byrne
Exploring targeted therapies for high-grade epithelial ovarian cancer utilising a novel patient-derived xenograft. - Gwo Yaw Ho
Targeted delivery of a synthetic microRNA mimic as a novel approach to treating cancer - Glen Reid

Friday →

Thursday, 12th February 27th Lorne Cancer Conference 2015

Opening Remarks/Session 1: Melanoma Genomics and Therapeutic Targets

Afternoon Tea

Plenary Session 1

Dinner

Poster Session 1